UCB Expands Autoimmune Pipeline with $2.2B Candid Therapeutics Acquisition

A strategic move into bispecific antibodies as pharma races to redefine autoimmune treatment through targeted immune cell depletion and next-generation T cell engagers

UCB strengthens its position in autoimmune disease with the acquisition of Candid Therapeutics, signalling a deeper industry shift toward bispecific antibodies and next-generation immune reprogramming therapies.

UCB has agreed to acquire Candid Therapeutics in a deal worth up to $2.2 billion, gaining access to a portfolio of bispecific antibody therapies targeting autoimmune diseases through selective immune cell depletion and immune system “reset” mechanisms.

The acquisition adds multiple early-stage assets, including cizutamig and CND261, to UCB’s immunology pipeline and reinforces its strategy of building a next-generation portfolio in immune-mediated diseases.

A Strategic Bet on Bispecific Antibodies in Autoimmunity

The centrepiece of the deal is Candid’s bispecific antibody platform, which redirects T cells to eliminate pathogenic B cells implicated in autoimmune disease progression.

Lead asset cizutamig targets BCMA on B cells and is being evaluated across multiple autoimmune indications following early clinical studies in more than 100 patients, including both multiple myeloma and immune-mediated diseases.

Unlike traditional immunosuppressants, these therapies aim to achieve deeper disease control by selectively removing disease-driving immune cells rather than broadly suppressing immune function.

UCB has positioned the asset as a potential “best-in-class” T cell engager, highlighting its potential to reduce harmful immune activation while minimising risks such as cytokine release syndrome.

Why This Deal Matters Now

This acquisition reflects a broader acceleration in autoimmune drug development toward targeted immune cell depletion strategies, particularly:

• Bispecific antibodies replacing broad immunosuppression approaches

• T cell engagers emerging as scalable alternatives to cell therapy

• Precision immunology targeting specific immune cell pathways

• 
  

Pharma companies are increasingly exploring approaches that “reset” immune dysfunction rather than simply controlling inflammation, with growing interest from major players across immunology and oncology.

Recent deals in this space from companies such as Merck, Sanofi, and Gilead highlight the competitive intensity behind this emerging therapeutic class.

What This Means for the Industry

The UCB–Candid deal underscores three key industry trends:

• Autoimmune disease is becoming a major frontier for bispecific antibody innovation

• T cell engager platforms are attracting increasing M&A activity

• Pharma is prioritising mechanism-driven immune reprogramming over symptomatic control

• 
  

At the same time, competition is intensifying as companies race to define the first wave of scalable, next-generation autoimmune therapies that can move beyond chronic immunosuppression.

UCB’s acquisition signals a clear intent to establish leadership in this emerging category.

Summary

UCB’s $2.2 billion acquisition of Candid Therapeutics highlights a decisive shift in autoimmune drug development toward bispecific antibody platforms and immune reset mechanisms.

As the field moves away from broad immunosuppression, pharma companies are increasingly competing to define targeted immune cell therapies that could reshape long-term treatment strategies in autoimmune disease.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com